WISELEAF SCIENTIFIC VENTURES

BIODEGRADABLE POLYMERS IN DRUG DELIVERY AND TISSUE ENGINEERING

CHAPTER-8

Regulatory, Safety and Future Directions of Biodegradable Polymer-Based Therapies

Santosh Sadekar

Anandi Pharmacy College, Kalambe tarf Kale, Kolhapur, Maharashtra, India

Corresponding Author Email : santoshsadekar003@gmail.com

Abstract

Biodegradable polymer-based nanocarriers have one of the more puzzling track records in contemporary pharmaceutical science: enormous preclinical literature, an expanding base of mechanistic understanding, and a thin line of approved products that does not match the output. This chapter is an attempt to explain that gap honestly, rather than catalog what the systems can theoretically do. The argument running through it is that the barriers are not primarily in the polymer chemistry or the pharmacology. They are in the toxicological testing framework, in manufacturing processes that cannot survive the transition from flask to GMP plant, and in regulatory systems that are still catching up to what nanoscale drug delivery actually requires of them.

The chapter covers polymer degradation products and what they genuinely do in tissue at physiologically relevant concentrations, not the reassuring metabolic accounting that tends to appear in early submissions. It examines the protein corona problem and why ISO 10993 biocompatibility standards, written for macroscale implants, leave important questions unanswered for nanoparticle systems. It works through manufacturing, where the gap between a characterised laboratory batch and a GMP clinical supply lot has ended more programmes than the literature reflects. The regulatory section compares FDA, EMA, and CDSCO frameworks with attention to where they converge, where they genuinely differ, and where combination product ambiguity creates delays with no good scientific justification.

Case studies of approved products and terminated clinical programmes are used not to list outcomes but to extract what each failure actually revealed. BIND-014 is taken seriously rather than filed away as a data point. The chapter closes on emerging tools, including AI-assisted formulation design, PBPK modelling, and organ-on-chip systems, with an effort to say something honest about where each one sits on the path to clinical utility rather than where it aspires to sit.

Keywords : biodegradable polymers; nanocarriers; regulatory toxicology; clinical translation; nanomedicine; PLGA; drug delivery

8.1. Introduction

Something strange happens when you look at biodegradable polymer nanocarrier research as a body of work rather than individual papers. The preclinical science is genuinely impressive. PLGA nanoparticles loaded with paclitaxel outperform free drug in tumour models by almost any metric you choose. Chitosan particles can traverse mucosal barriers. Dendrimers can carry nucleic acid cargoes into cells that would otherwise be pharmacologically inaccessible. [1] The polymer scaffolds disappear after delivering their payload, which solves the retrieval problem that has limited non-degradable implanted systems for decades. [2] Surprisingly, the total number of biodegradable polymer nanocarrier products that have successfully passed a pivotal trial and have been launched in the market is extremely limited that one can even memorize it within an afternoon.

A look at the ClinicalTrials.gov listing gives a numerical perspective to the issue: majority of the polymer nanocarrier candidates that proceed to Phase I or II do not get to pivotal trials. Lack of efficacy, product manufacturing issues and regulatory complications were responsible for most the attrition cases, in roughly that order of incidence. [3] Of the formulations published annually, the ones that make it to regulatory submission tend to be microsphere depot systems with well-understood release mechanisms, not the multifunctional targeted platforms that appear on conference slide decks. [4] The distance between what the field is inventing and what the field is translating has not narrowed over the past decade.

Three explanations recur in the critical literature. The toxicological evaluation toolkit was built for small molecules and adapted imperfectly for systems whose colloidal behaviour, protein adsorption dynamics, and size-dependent tissue distribution are categorically different from anything those assays were designed to assess. [5] Regulatory guidance from the FDA, EMA, and CDSCO has moved in the right direction but remains fragmented, particularly around characterisation requirements specific to nanoscale systems. [6] And manufacturing processes that perform well at laboratory scale frequently fail to transfer to the production volumes needed for clinical supply, for reasons rooted in fluid dynamics that have nothing to do with the formulation science.

This chapter works through those three explanations systematically. The work is based on the FDA, EMA, and CDSCO guidance documents, the ISO 10993 biocompatibility standards, the ICH Q and S series, and product case studies from approved and terminated development programmes. It is not the intention here to showcase the preclinical potential of these systems, which has been very comprehensively done elsewhere, but to identify the specific obstacles that have prevented most of the them from getting to patients.

8.2. Biodegradable Polymer-Based Nanocarriers: Definitions and Scope

8.2.1 What the Term Actually Covers

Biodegradable polymer nanocarriers are tiny colloidal particles ranging from 10 to 1000 nm in size, wherein a drug molecule is either dissolved trapped adsorbed, or covalently linked into a polymer matrix that is capable of hydrolysing or enzymatically breaking under physiological conditions. [7] The degradation products are metabolizable fragments cleared through normal routes. This is the defining feature, and the one most often used to justify safety assumptions that the evidence does not always support.

Classification matters here because the regulatory consequences differ. By structure, the main groups include nanospheres nanocapsules polymeric micelles dendrimers polyplexes, and hydrogel nanoparticles, each having a different way of drug loading and release behavior. [8] By polymer origin: naturally derived versus synthetic. By alteration status of the surface: PEGylated, ligand-conjugated, or unmodified. By ground of drug release: diffusion-controlled, erosion-mediated, or stimuli-triggered. The regulatory scope of characterisation necessary for a stimuli-responsive conjugated nanoparticle is far more strict than that for a simple PLGA nanosphere, and merging these structures in early development planning leads to difficulties downstream.

The distinction between biodegradable and bioerodable is worth keeping. Bioerodable systems lose material from the surface while the bulk remains intact, producing surface-erosion-driven release kinetics. Biodegradable systems like PLGA undergo bulk hydrolysis throughout the matrix simultaneously, which produces the biphasic release profile the field knows well but also creates the acid accumulation problem discussed in Section 4.

Table 8.1 : Classification, Degradation Mechanisms, and Applications of Biodegradable Polymers Used in Nanocarrier Formulations

Polymer	**Origin**	**Degradation Mechanism**	**Applications**	Limitations
PLA	Synthetic	Hydrolysis of ester bonds	Sutures, implants, anticancer NPs	Slow degradation; brittle at low MW
PLGA	Synthetic	Bulk and surface erosion; co-monomer ratio controls rate	Microspheres, vaccine delivery, cancer theranostics	Acid micro environment on hydrolysis; burst release variability
PCL	Synthetic	Slow hydrolytic degradation (2-4 yr in vivo)	Long-acting implants, scaffolds, wound dressings	Oligomeric accumulation; long-term clearance uncharacterised
PEG	Synthetic/semi	Renal clearance; chain cleavage	Stealth coatings, PEGylated liposomes	Anti-PEG antibodies detectable in 25-72% of blood donors
Chitosan	Natural (chitin)	Enzymatic (chitinase, lysozyme)	Gene delivery, mucosal vaccine, wound healing	Batch variability in deacetylation degree; animal-derived immunogenicity
Alginate	Natural (algae)	Ion exchange, enzymatic	Hydrogel scaffolds, cell and	Mechanical weakness in low-

			drug encapsulation	calcium environments
Gelatin	Natural (collagen)	Proteolysis (MMP-dependent)	Tissue engineering matrices, NP core	Cross-linking inconsistency; viral contamination risk in injectable use
Hyaluronic acid	Natural (ECM)	Hyaluronidase, ROS cleavage	Targeted delivery, cartilage regeneration	Faster degradation change; tumour hyaluronidase expression heterogeneous

8.2.2 Comparative Analysis Between Natural And Synthetic Polymers

The basis for the biocompatibility of natural polymers is that the molecules which they break down into are already present in our body. [9] Although the statement is theoretically correct, it is a highly simplified depiction of reality. For example, the characteristics of chitosan are dependent on the level of deacetylation, the response of alginate is related to the guluronate to mannuronate ratio, and cross-linking of gelatin is hardly ever the same between batches.

Synthetic polymers offer better compositional control. By changing the lactide-to-glycolide ratio, end-group chemistry, and molecular weight, the degradation rate of PLGA can be modulated, besides which, the regulatory approval of PLGA-based depot products gives a basis for the submission of new ones. [10] The underappreciated problem is what happens as PLGA degrades inside tissue. Progressive accumulation of lactic and glycolic acid oligomers can drive local pH below 4 at the core of a slowly vascularised matrix. Protein payloads denature. Nucleic acid cargoes degrade. Macrophages infiltrate. These effects appear in preclinical reports as minor histological findings and they should receive more sustained attention than they do. [11]

8.2.3 Degradation and Drug Release

The process of biodegradation takes place via hydrolysis of ester, amide, or anhydride bonds; enzymatic cleavage by endogenous hydrolases and proteases; or oxidative chain scission by reactive oxygen species in inflamed microenvironments. [12] PLGA displays bulk erosion mechanism, i.e. the whole matrix hydrolyses simultaneously instead of gradually from the surface inward. Autocatalysis is a significant aspect: acidic degradation products pile up in the core at a rate faster than diffusion can remove them, Because of this creating the conditions which destroy the stability of sensitive payloads.

Drug release is typically biphasic. A burst phase, driven by surface-adsorbed drug and loosely encapsulated material, is followed by a diffusion-and-erosion-controlled sustained release phase. [13] The burst is pharmacologically significant in oncology. An uncontrolled early spike that mimics free drug toxicity without the targeting benefit that justified the nanocarrier approach is hard to defend to a regulatory reviewer. Burst release variability across batches is also one of the more common reasons for critical quality attribute non-conformance in late-stage clinical supply manufacture, and it rarely receives adequate characterisation in Phase I submissions.

8.3. Applications in Drug Delivery and Tissue Engineering

8.3.1 Cancer Therapy

For the last three decades, the principle behind nanocarrier oncology has been the enhanced permeability and retention (EPR) effect. The irregular blood vessel structure in tumours makes it possible for large molecules and nanoparticles to build up in tumours at much higher levels than in normal tissues, at the same time, impaired lymphatic drainage reduces their removal. [14] In mouse xenograft models, PLGA nanoparticles containing paclitaxel, doxorubicin, or cisplatin have always been superior to the free drug.

The problem is that human solid tumours are not murine xenografts. Vascular permeability varies across tumour types, across patients with the same tumour, and across regions within a single tumour. [15] A nanocarrier strategy built around EPR cannot be assumed to work; it has to be demonstrated, in a model that actually reflects the patient population being targeted. Most

preclinical programmes skip that step. This matters enormously for Phase II outcomes, as BIND-014 showed.

Active targeting, which adds receptor-mediated uptake on top of passive accumulation by conjugating folate receptors, transferrin, HER2-directed fragments, or aptamers to the nanoparticle surface, was intended to compensate for EPR heterogeneity. [16] It introduces formulation complexity that multiplies regulatory requirements. A conjugated nanocarrier needs toxicological characterisation of the conjugation chemistry under physiological conditions, an immunological profile for the targeting ligand, and evidence that off-target receptor interactions in healthy tissue are not pharmacologically relevant. [17] Few early-stage programmes have the resources to address all three adequately.



Figure 8.1. EPR Effect: Preclinical Murine Xenograft Model vs Human Solid Tumour - The Source of the Translation Gap

8.3.2 Gene Delivery

Cationic biodegradable polymers like chitosan, PEI-modified PLGA, and poly(beta-amino esters) interact electrostatically with nucleic acids, which are negatively charged and compact

them into polyplexes. Besides carrying the cargo, such complexes also shield the cargo from being degraded by serum nucleases and promote endocytic uptake. [18] Escape from the endosome is the major reason for the loss of efficiency of many systems in vivo. PEI nanoparticles escape from endosomes through the proton sponge effect while PBAE nanoparticles escape with the help of membrane disruption that is sensitive to pH changes. Yet, in vivo neither of these mechanisms is as efficient as it appears from cell culture results because in standard transfection assays the absence of plasma proteins, immune cells, and competing uptake pathways is not taken into account.

The toxicological profile of cationic gene carriers is more negative than that of neutral or anionic ones. A high surface charge density makes the carriers haemolytically active towards erythrocytes, capable of activating complement, and able to cause pro-inflammatory macrophage responses. [19] Nowadays, regulatory authorities are asking for immunotoxicology panels to be expanded for cationic nanocarriers: complement activation assays (CH50, Bb fragment), cytokine release studies, PBMC stimulation indices. Each of these factors contributes to the cost and time that programmes already working under funding pressure have to bear.

8.3.3 Vaccine Delivery

PLGA microsphere vaccine systems that sustain antigen release over several weeks could, in principle, enable single-administration schedules that eliminate the need for boosters. That would matter in resource-limited settings. [20] Chitosan nanoparticles are able to penetrate the mucosal epithelial barriers and Because of this evoke secretory IgA responses, unlike parenteral vaccines. [21] During the COVID-19 pandemic, the regulatory authorities set a regulatory precedent by approving lipid nanoparticle-based vaccines, which in turn influenced their perception and assessment of polymer-based vaccine systems.

When it comes to the regulatory submission for a polymer-based vaccine, satisfying two rather separate sets of requirements is essential: one set of requirements is vaccine-specific and focuses on aspects like immunogenicity, safety of the adjuvant, and cold chain stability, while the other set is devoted to nanomedicine-specific requirements like physicochemical

characterization and in vitro release. The intersection is demanding, and the precedent base for navigating it is thin compared to conventional vaccines or standard nanoparticle drug products.



Figure 8.2 Polymer-Based Vaccine Systems: Dual and Intersecting Regulatory Requirements

8.3.4 Tissue Engineering

One of the most widely used methods in the field of tissue regeneration involves using sacrificial or drug-loaded polymeric micro/nanofibrous scaffolds as structural supports for cell ingrowth, and at the same time, as vehicles for controlled release of growth factors or antimicrobials. Different fabrication techniques like electrospinning, 3D printing, and freeze-drying are utilized in producing PCL and PLGA scaffolds. [22] Another aspect that needs to be taken into account when designing scaffolds is the matching of their mechanical properties to those of the target tissue. This Yet is a challenging engineering problem: for example, the elastic modulus of cortical bone is about 17 GPa, whereas cartilage is approximately 1 MPa. Also,

degradation rates of scaffolds must remain in harmony with the pace of new tissue generation, which itself can differ among patients and body parts.

In the United States, a biodegradable scaffold carrying a drug payload may fall under CDRH and CDER jurisdiction simultaneously, depending on which mode of action is judged primary. [23] That classification decision, made by the Office of Combination Products, has major consequences for the scope and cost of required studies. Several programmes have lost 12-18 months to OCP determinations before a single IND enabling study was run. Getting regulatory classification right at the start of development, rather than after significant investment has been made, is one of the more important and least discussed aspects of strategy in this space.

8.4. Toxicological Challenges

8.4.1 Degradation Products and Local Tissue Responses

The standard safety argument for PLGA and PLA systems is that lactic and glycolic acid are normal metabolic substrates, so degradation products are inherently safe. This framing is too simple. The local concentration of those products at the site of polymer hydrolysis can substantially exceed systemic physiological levels, particularly within slowly vascularised compartments like cartilage or the core of a poorly perfused tumour. [24] Local pH can drop below 4. At that pH, macrophages infiltrate, osteoclasts activate at bone implant interfaces, and co-encapsulated protein payloads denature before they can act. These observations appear in preclinical histology reports as minor findings and are rarely followed up with mechanistic investigation.



Figure 8.3 PLGA Bulk Hydrolysis: Acid Accumulation and Local pH Depression at the Implant Core

PCL degrades more slowly than PLGA, with in vivo half-lives of two to four years. Less local acidity, but a different problem: partially degraded oligomeric species that accumulate in tissues of patients with impaired phagocytic capacity. Immunosuppressed oncology patients, elderly patients with age-related MPS decline, patients with hepatic dysfunction from prior chemotherapy. [25] The FDA biocompatibility guidance for combination products requires individual characterisation of all identifiable degradation products. In practice, identifying and quantifying oligomeric intermediates against the complexity of biological matrices is analytically demanding, and the requirement is often satisfied incompletely in early-phase submissions without reviewers explicitly flagging the gap.

8.4.2 Cytotoxicity Assays and Their Limits

In vitro cytotoxicity studies of nanocarriers produce results that are more difficult to interpret than is generally acknowledged. Nanoparticles with coloured payloads, fluorescent labels, or metal ion contaminants interfere with the absorbance measurements on which MTT, resazurin, and LDH assays depend. [26] The interference can run in either direction: nanoparticles that

absorb at the assay wavelength artifactually reduce apparent cytotoxicity; those that absorb formazan products inflate it. The magnitude of the error is formulation-specific and often not assessed.

Cell line selection adds to the issue. A549 and HeLa cells end up being the default choice for nanotoxicology in vitro mainly due to logistical reasons and not because they can effectively forecast the behavior of the actually relevant cells like primary human endothelial cells lining the vasculature, hepatocytes responsible for processing nanoparticles, and Kupffer cells of the liver. These cell types exhibit their metabolic properties, receptor expression, and phagocytic abilities quite differently from cancer cell lines. That means, merely relying on A549 results to predict hepatocyte responses is not justifiable at all without the support of bridging data.

8.4.3 Immunogenicity: CARPA and Anti-PEG Antibodies

Complement activation-related pseudoallergy is the best-characterised acute immunological adverse event associated with intravenous nanoparticle administration. The mechanism involves C1q recognition of polyanionic nanoparticle surfaces or alternative pathway activation on hydroxylated polymer chains, triggering a cascade that produces cardiopulmonary distress, bronchospasm, and hypotension. It has been documented clinically with PEGylated liposomal products and is a genuine risk for any intravenously administered biodegradable polymer nanocarrier. [27]

PEG was adopted as the standard stealth coating in part because it was assumed to be immunologically inert. That assumption has been revised. Anti-PEG IgM and IgG antibodies can be found in 25-72% of healthy blood donors in industrialised countries, indicating their exposure to food additives, cosmetics, and pharmaceutical products, most recently the mRNA vaccines during the COVID-19 period. [28] In case of PLGA-PEG nanoparticle programmes, patients who have pre-existing anti-PEG antibodies might get their nanoparticles cleared rapidly, get reduced therapeutic exposure and in some cases, even get hypersensitivity reactions. IND packages normally do not sufficiently cover this issue.

Nanoparticle internalization by phagocytic cells contributes to the production of intracellular reactive oxygen species as part of the normal antimicrobial phagosomal defense mechanism.

If nanoparticle loading continues to induce ROS production beyond the normal levels, the effects would be lipid peroxidation of lysosomal membranes, NLRP3 inflammasome activation, and the release of IL-1beta and IL-18. [29] The inflammatory response that ensues is often out of proportion to the clinical condition and is not easy to predict based on standard cytotoxicity assays.

Table 8.2 : Toxicological Assessment Methods for Biodegradable Polymer Nanocarriers

Method	**Study Type**	**Parameter Assessed**	**Limitations**
MTT/MTS assay	In vitro	Mitochondrial metabolic activity	NPs of certain colors cause optical interference; distinguishing between apoptosis and necrosis is impossible
LDH release assay	In vitro	Membrane integrity	NPs cause colorimetric interference; enzymes degrade over time
ROS detection (DCFH-DA)	In vitro/In vivo	Oxidative stress	The probe is unstable at physiological pH; auto-oxidation artefacts cause quantification problems
Comet assay	In vitro/Ex vivo	DNA strand breaks / genotoxicity	The method is internationally validated; it is a very time consuming; work-consuming; scoring may vary between different labs
Haemocompatibility (ISO 10993-4)	In vitro	Haemolysis, platelet aggregation	It is a must for IV formulations; But, it is unable to predict CARPA risk

Macrophage activation (TNF-a, IL-6)	In vitro/In vivo	Pro-inflammatory signalling	Gives mechanistic details; Though, due to differences in cytokine species, the results may not be fully applicable to humans
Repeated-dose toxicity (OECD 407/408)	In vivo (rodent)	Systemic organ toxicity; NOAEL	26-week maximum is not suitable for polymers that remain in vivo for 2-4 years
Biodistribution (ICP-MS, fluorescence)	In vivo	Organ accumulation and clearance	Quantitative but tracer stability must be independently validated; signal may not represent intact NPs
PBPK modelling	In silico	Tissue distribution prediction	Parameter validation datasets for NPs are sparse; uncertainty propagates to dosing recommendations

8.4.4 Organ Accumulation and the Long-Term Safety Gap

The fate of nanoparticles administered systemically is controlled by the mononuclear phagocyte system. The liver Kupffer cells, splenic macrophages, and lung alveolar macrophages are very effective in removing opsonised particles. Most rodent biodistribution studies show that the liver uptake of PLGA and PLA nanoparticles together represents 20-60% of injected dose within 24 hours. [30] The downstream question, what sustained hepatic nanoparticle loading does to Kupffer cell function, hepatocyte metabolism, and biliary excretion of degradation products in oncology patients whose livers are already under strain from prior chemotherapy, has not been studied adequately. The published literature rarely extends past four weeks post-administration.

Standard preclinical repeat-dose toxicity studies run to 26 weeks in rodents. For a polymer system that may persist structurally intact for two to four years in vivo, that study duration

answers a narrow slice of the safety question. [31] Multi-year primate studies would begin to address the gap, but their cost and ethical burden put them beyond reach for most academic and early-stage industrial sponsors. The field has lived with this limitation for a long time without finding a satisfying way around it.



Figure 8.4 Systemic Biodistribution of PLGA Nanoparticles After IV Administration and the Long-Term Safety Study Duration Gap

8.4.5 Protein Corona: The Problem ISO 10993 Does Not Address

Within seconds of entering the bloodstream, a nanoparticle acquires a layer of adsorbed plasma proteins. The soft corona that forms first, enriched in high-abundance proteins such as albumin and fibrinogen, is displaced over time by a hard corona of lower-abundance proteins with higher surface affinity. [32] By the time a nanoparticle reaches a Kupffer cell or an endothelial cell, what it presents on its surface is not the engineered surface the formulation scientist characterised in phosphate-buffered saline. It is the protein corona. The designed PEG brush, the targeting ligand, the zeta potential measured before administration, none of these are what the cell sees.

ISO 10993-5 (cytotoxicity), 10993-6 (local implant effects), 10993-10 (sensitisation), and 10993-11 (systemic toxicity) are the major biocompatibility standards that are mostly used for biodegrable polymer systems. They were First and foremost developed for macroscale solid implants and didn't consider aspects like protein corona formation, colloidal stability in biological fluids, or size-dependent biodistribution. When ISO 10993 is used for a nanoparticle product, it results in a characterisation package that meets formal requirements but does not identify the most clinically relevant safety signals. This is something that regulatory agencies are aware of. So far, specific amendments to ISO 10993 for nanoparticles have not been made public.

8.5. Regulatory Challenges

8.5.1 The Combination Product Classification Problem

A biodegradable polymer nanocarrier incorporating a drug payload may be classified as a drug, a device, or a combination product under US regulations, depending on its primary mode of action. The FDA's Office of Combination Products makes that determination, and the consequences are substantial: which FDA centre reviews the product, which regulatory pathway applies, which GMP regulations govern manufacturing. [33] A PLGA microsphere delivering leuprolide for prostate cancer is clearly a drug; CDER reviews it. A PLGA scaffold releasing a bone morphogenetic protein to support spinal fusion is genuinely ambiguous, and the OCP determination can take 12-24 months when formally contested.

In the European Union, polymer systems whose therapeutic effect involves both structural contribution from the scaffold and pharmacological contribution from a drug payload may require parallel consultation with the EMA and a Notified Body under MDR 2017/745. [34] The 2021 Commission borderline guidance helps but does not resolve the core ambiguity for nano-enabled combination products. A sponsor who makes the wrong initial classification call, then discovers it after significant CMC and nonclinical investment, faces a repositioning exercise that can cost years.

8.5.2 FDA Framework

The FDA takes a product-specific, case-by-case approach to nanomedicine regulation rather than establishing a size threshold that triggers categorical special requirements. [35] The flexibility this provides is real. So is the unpredictability. Sponsors cannot reliably project the data package that will be required until they have sat in a pre-IND meeting with the relevant review division.

Core FDA expectations for biodegradable polymer nanocarrier IND submissions include full physicochemical characterisation: particle size distribution by DLS and TEM or NTA, zeta potential, polydispersity index, encapsulation efficiency, and in vitro drug release in biologically relevant media. Manufacturing reproducibility across at least three independent batches is expected before IND submission, not after. The nonclinical pharmacology and toxicology package follows ICH S9 for oncology products or M3(R2) for others. [36] For polymers without prior human exposure history, the CMC review requires monomer identity and purity, copolymer composition, molecular weight distribution, residual solvent levels per ICH Q3C, and elemental impurities per ICH Q3D.

8.5.3 EMA Framework

EMA has addressed nanomedicine through a series of reflection papers on non-clinical studies for generic nanoparticle products, surface coatings, and block copolymer micelles. These are soft-law documents, not binding regulation. [37] They signal what the agency is thinking, and they leave enough interpretive space that two review teams could reach different conclusions about the same characterisation dataset.

A particular challenge for European submissions is the comparability requirement. When manufacturing scale increases or manufacturing site changes, EMA expects demonstration that nanoparticle critical quality attributes are preserved. [38] For nanoparticle systems whose particle size and surface properties depend on mixing dynamics, temperature gradients, and solvent removal rates that change non-linearly with equipment scale, comparability is technically demanding in ways that are not always appreciated during early planning. The

PRIME designation for nanomedicines addressing unmet need provides enhanced regulatory dialogue that has helped some sponsors work through this before filing.

8.5.4 CDSCO and the Indian Context

India's nanomedicine regulatory structure is mainly based on the Drugs and Cosmetics Act 1940 and the New Drugs and Clinical Trials Rules 2019. The CDSCO issued a draft guidance on nanomedicine drug products containing nanomaterials in 2019, which corresponds to FDA physicochemical characterization expectations. It has not been finalized So it does not have any compulsory legal force. [39] The effective result is the lack of harmony: different CDSCO review teams give different interpretations of the same data, sponsors are unable to foresee what will be asked of them, and the official pre-submission dialogue mechanisms that FDA and EMA provide are only minimally available.

This matters beyond India because India's pharmaceutical sector accounts for a significant share of global generic drug output, and its academic research community generates substantial volume in the biodegradable nanocarrier space. ICH membership since 2016 and participation in WHO collaborative procedures offer the most tractable path toward alignment with international standards. [40] The ICH Multidisciplinary Expert Working Group on Nanomaterials is developing guidance that, once finalised, would give Indian sponsors a more stable international framework to build on.

Table 8.3 : Comparative Regulatory Analysis: FDA (USA), EMA (Europe), CDSCO (India)

Parameter	**US FDA**	**European EMA**	**India CDSCO**
Classification	Drug, device, or combination products used as main mode of action; OCP formal determination would may be necessary	It may need parallel EMA and Notified Body consultation under MDR 2017/745	New Drug or IND equivalent, no nanomedicine specific pathway exists

Primary guidance	Nanotechnology Regulatory Science Research Plan (2022); product-specific guidance documents	Reflection Papers (2009-2024); non-binding soft law	Draft guidelines on Nanomedicines (2019); It's not confirmed, no binding
Physicochemical characterisation	Size (DLS, NTA, TEM), PDI, zeta, EE, in vitro release; 3-batch reproducibility needs pre-IND	Similar to FDA; CQAs and QbD design space mandatory for PRIME submissions	Mirrors FDA expectations in draft guidance; not consistently enforced at review
Accelerated pathway	Breakthrough Therapy, Fast Track, RMAT is available	PRIME designation; conditional marketing authorisation	No fast-track mechanism specific to nanomedicines which are currently available
GMP framework	21 CFR Parts 210/211; ICH Q8-Q12 QbD requirements	EU GMP Annex 1 revised 2022 for sterile manufacturing	Schedule M; WHO GMP connected
Post-market surveillance	REMS programmes; periodic pharmacovigilance reports	Periodic Safety Update Reports (PSURs)	Schedule Y ADR reporting; limits formal nanovigilance infrastructure



Figure 8.5: Comparative Regulatory Readiness for Biodegradable Polymer Nanocarrier Review: FDA vs EMA vs CDSCO

8.5.5 GMP, Quality by Design, and the Sterilisation Problem

Ensuring GMP compliance when manufacturing nanoparticle products involves overcoming different types of process issues than those faced during the production of small molecules. For instance, the physical properties such as particle size, the extent of encapsulation, and the outermost chemical composition of nanoparticles are very susceptible to changes in various parameters like polymer concentration, rate of antisolvent injection, speed of mixing, temperature, and lyophilisation cycle parameters. Also, these features do not scale linearly with the change in equipment design. [41] For example, a batch produced at flask scale of 50 mL might have very different characteristics when produced at 5 L pilot scale with geometrically

scaled-up equipment, not due to any error in the formulation, but because the Reynolds number which determines the mixing of fluids changes with the volume of the vessel. Such change is well documented in engineering literature. More often than not, it is not properly taken into consideration in the developmental plans at an early stage.

Quality by Design, as put in the terms of ICH Q8(R2) Q9 Q10, and Q11, offers the proper method: determining critical quality attributes, establishing their correlation with critical process parameters via designed experiments, and designing a verified design space. [42] Both FDA and EMA are supportive of QbD-based submissions for nanoparticle products. The missing piece is the ability to carry out. Producing the multivariate experimental data that are required to delineate a reliable design space necessitates the availability of analytical tools and formulation development staff, which most academic groups as well as early-stage companies are not able to gather without collaboration with the industry.

There is still no completely satisfactory method for sterilisation of biodegradable polymer nanocarriers. Most polymer matrices and drug payloads get destroyed when autoclaving at 121 degrees Celsius. Gamma irradiation at sterilisation doses around 25 kGy results in chain scission in PLGA and PCL causing a shift in molecular weight distribution and a change in drug release kinetics. [43] Aseptic fill-finish under Grade A conditions is currently the standard alternative. It is effective Still it is costly, needs a thorough validation of the process for sterility assurance, and raises the manufacturing cost per unit quite Much against products that are terminally sterilised.

8.6. Clinical Translation Barriers

8.6.1 Scale-Up

The processes used in academic laboratories to produce nanoparticles, nanoprecipitation, emulsion-solvent evaporation, double emulsion, ionic gelation, are difficult to scale reproducibly. [44] Batch processes in flasks are governed by mixing dynamics that change non-linearly when vessel volume increases. Particle size and polydispersity achieved at 1-10 mL scale cannot always be matched in 1-100 L manufacturing vessels with geometrically scaled

equipment. This is not a formulation failure; it is a process engineering constraint that needs to be addressed at the scale-up stage, not discovered during clinical supply manufacture.

Continuous microfluidic manufacturing offers better mixing kinetics control and has produced narrow-size-distribution PLGA and lipid-polymer hybrid nanoparticles at clinically relevant throughputs in research settings. The barriers to GMP adoption are the capital cost and the limited regulatory precedent for continuous nanoparticle manufacture as a platform for approved drug products. That precedent base is growing, but slowly.

Most nanoparticle formulations require lyophilisation as polymer and payload hydrolytic degradation in aqueous suspension severely limits shelf-life. [45] The freeze-drying cycle brings its own challenges: ice crystal formation during freezing, dehydration, and reconstitution step can cause particle aggregation and change drug release profiles if cryoprotectant selection and cycle development are not rigorously optimised. Mannitol, sucrose, and trehalose at system-specific concentrations are the usual choices. What is good for laboratory scale in a small-format dryer may not be applicable to GMP lyophilisation in large-scale equipment having different heat transfer characteristics.



(B) CQA Consequences of Mixing Regime Change at Scale-Up

CQA	Lab (100 mL)	GMP (50 L)	Outcome
Particle Size (Dh)	120 ± 8 nm	198 ± 47 nm	✗ Fails CQA
PDI	0.11	0.28	✗ Fails CQA
Encapsulation Efficiency	82%	61%	✗ Reduced
Burst Release (2h)	12%	31%	✗ Variability
Zeta Potential	−28 mV	−19 mV	⚠ Borderline

Note: Values illustrative; based on published scale-up studies (Rao & Geckeler 2011; Fredenberg et al. 2011). CQA = Critical Quality Attribute.

Figure 8.6 GMP Scale-Up Challenge: Mixing Dynamics (Reynolds Number) and Critical Quality Attribute Consequences

8.6.2 The Reproducibility Problem

A 2023 systematic review found that fewer than 25% of published biodegradable nanoparticle formulations provided sufficient characterisation data for independent replication, and that particle size measurements from DLS, NTA, and TEM frequently gave non-concordant results within the same laboratory. [46] This matters practically, not just academically. The preclinical safety and efficacy database that regulatory agencies evaluate when reviewing IND applications is built on published studies, and if those studies cannot be reproduced, the database they form is less reliable than it appears.

The cost of advancing a nanocarrier formulation from laboratory to IND-enabling studies is estimated at USD 2-5 million. [47] In academic laboratories and small companies In particular which innovate the most in this field, the cost is prohibitive without industrial partnership or persistent public funding. Nanoparticle research knowledge gap versus GMP manufacturing in academic sphere is very real also: writing for regulation, process engineering, analytical method validation and clinical operations are not the skills that university pharmacy departments should develop. Time and resources that early-stage programmes rarely have are needed to bridge them.

8.6.3 Why Animal Models Mislead

Subcutaneous xenograft tumours in athymic mice overestimate EPR-mediated nanoparticle accumulation relative to orthotopic or syngeneic models that better reproduce human tumour vascular architecture. [54] The preclinical model commonly used to justify oncology nanocarrier development is not a simplified version of the clinical situation. In some respects it is systematically misleading. Regulatory agencies have begun requiring more explicit justification of model choice in nanoparticle IND applications.

Species differences in complement activation, phagocytic organ anatomy, and MPS capacity add further noise to the translation. Rodent and human complement systems respond differently to the same nanoparticle surface. Porcine models better predict CARPA-type reactions but are expensive and not routinely available. No in vitro assay for human complement activation that

is both mechanistically credible and widely accepted by regulatory agencies currently exists. The field has managed this gap by combining animal data with acknowledged limitations and in vitro assays whose clinical correlation is uncertain, which is not a satisfying state of affairs.

8.7. Case Studies: What the Approvals and Failures Actually Reveal

8.7.1 Lupron Depot

Lupron Depot, which was approved by the FDA in 1989, is the primary standard by which most PLGA depot submissions are implicitly assessed. PLGA microspheres that contain leuprolide acetate enable a monthly or quarterly release for hormone-sensitive prostate cancer and endometriosis. [50] Through its approval, it set the characterisation requirements, the approach to manufacturing validation, and the pharmacokinetic-pharmacodynamic evidence standard that subsequent PLGA depot programmes have adopted. The sizes of the microspheres are about 20-100 micrometres, so it is not a nanoparticle product in the modern sense, but the regulatory setup that it established has been the longest-lasting contribution to the field.

8.7.2 Ozurdex and Abraxane

Ozurdex, which is a implant in the form of a rod made up of PLGA that releases the drug dexamethasone in the vitreous humor, was given the go-ahead in 2009 for use in patients with macular edema resulting from retinal vein occlusion. [51] What is significant from the regulatory standpoint is that it was able to go through the combination product route: CDER review together with CDRH consultation, classification based on the primary mode of action of the drug, and In reality it was a delivery method confined to one part of the body which made the questions about biodistribution and systemic safety probably much easier. A well-conducted Phase III RCT was used as the basis for the clinical evidence package.

Abraxane, albumin-bound paclitaxel nanoparticles approved in 2005, illustrates something different. Its regulatory rationale was not tumour targeting. It was the elimination of Cremophor EL, the solubiliser in conventional paclitaxel responsible for infusion hypersensitivity. [52] The argument was straightforward: equivalent or superior clinical outcomes, better tolerability profile. This is probably the most underappreciated lesson from the approved nanoparticle

product list. A nanocarrier does not need a targeting story to get approved. Meaningful improvement on a specific, well-characterised clinical problem is sufficient if the evidence is there.

8.7.3 BIND-014

BIND-014 was a PLGA-PEG nanoparticle carrying docetaxel, conjugated to a small molecule targeting prostate-specific membrane antigen. Preclinical xenograft data showed approximately 10-fold superior tumour accumulation versus free docetaxel. [53] Two Phase II studies of in non-small cell lung cancer and urothelial carcinoma showed the safety of the drug to be acceptable But the response rates were low and did not merit from now on. The program was terminated in 2016.

The failure of BIND-014 is worth examining directly. The preclinical data was not wrong within its own framework. In the xenograft models used, the compound performed as reported. The problem is that subcutaneous xenografts in immunocompromised mice systematically overestimate EPR-dependent nanoparticle accumulation relative to what occurs in human tumours with heterogeneous vasculature and an intact immune microenvironment. The testing framework predicted clinical success; the clinical trials revealed that the framework was inadequate. That is a different failure mode from a chemistry failure or a manufacturing failure, and it requires a different corrective response: better preclinical models, not better nanoparticles.

Table 8.4. Selected FDA-Approved and Clinically Notable Biodegradable Polymer Drug Products

Product	Polymer System	Drug	Status	Key Lesson
Lupron Depot	PLGA microspheres	Leuprolide acetate	FDA approved 1989	PLGA regulatory template was established by this product; this is still considered the

				primary example for depot submissions
Risperdal Consta	PLGA microspheres (MEDISORB)	Risperidone	FDA approved 2003	Schizophrenia durability in administration by IM biweekly dosing was a game changer; the clinical usefulness was evident and measurable
Ozurdex	PLGA rod implant	Dexamethasone	FDA approved 2009	This product successfully followed the combination product regulatory pathway; The confinement within the anatomy let the safety requirements be minimal
Abraxane	Albumin-bound NPs	Paclitaxel	FDA approved 2005	The main focus for approval was on drug tolerability, without demonstrating drug targeting; clinically, no targeting story is needed
Bydureon	PLGA microspheres	Exenatide	FDA approved 2012	GLP-1 was released once-weekly; it validated that the value of the PLGA depot is not limited to oncology only
BIND-014	PLGA-PEG NPs (targeted)	Docetaxel	Phase II; terminated 2016	EPR was greatly overestimated in the preclinical model; the

				scientific part was not wrong but the testing setup did not fit the purpose
CALAA-01	Cyclodextrin polymer NPs	siRNA (RRM2)	Phase I; discontinued	siRNA-NP human trial safety was manageable but in vivo siRNA delivery efficiency was insufficient

8.8. Economic and Commercialisation Barriers

Development from lead formulation to IND costs roughly USD 2-5 million. Full clinical development in oncology costs USD 100-500 million. [47] Manufacturing is more expensive than for small molecules because the process complexity, sterilisation requirements, and nanoparticle-specific quality control add costs that standard pharmaceutical manufacturing infrastructure does not cover. The pricing needed to recover those costs puts approved nanocarrier products out of reach for health systems in low- and middle-income countries.

For conditions where controlled polymer-based delivery could genuinely help, tuberculosis, malaria, neglected tropical diseases, almost no commercial development exists. [49] The development pipeline is concentrated in oncology and neurological disorders in high-income markets. That concentration reflects commercial logic, not clinical need, and it represents a failure of the innovation ecosystem to direct this technology toward where the burden of disease actually sits.

Foundational polymer chemistry patents have largely expired, but manufacturing method patents, formulation patents, and device patents on specific production approaches create freedom-to-operate complexity that requires careful analysis before significant capital is committed. Payors in major markets have also raised the evidence bar for reimbursement: pharmacokinetic advantage over existing treatment is not sufficient. Clinical benefit, measured

in outcomes that matter to patients, has to be demonstrated. That is a higher hurdle than the field initially anticipated.

8.9. Emerging Approaches

8.9.1 AI in Formulation Design

Deep learning models trained on PLGA nanoparticle formulation datasets have demonstrated the ability to predict particle size, encapsulation efficiency, and release profiles from polymer molecular weight, drug-to-polymer ratio, stabiliser concentration, and processing conditions, with accuracy comparable to conventional response surface designs. [55] Compressing a 12-18 month experimental optimisation programme down to a fraction of that time is a real benefit.

The regulatory acceptance of AI-generated formulation data is at an early stage. The FDA's 2021 discussion paper on AI in drug development requires prospective experimental confirmation of model predictions, documentation of training dataset composition and model architecture, and inclusion of performance metrics in regulatory submissions. [56] The more fundamental concern is training data quality. Models built primarily on published formulation literature are trained on a systematically biased sample: successful formulations are published at far higher rates than failed ones. A model that has never seen a failed formulation will not be a reliable guide to formulation decisions where failure is the common outcome. Correcting this requires access to unpublished industry datasets, which sponsors have no current incentive to share.

8.9.2 Stimuli-Responsive Systems

pH-responsive, redox-responsive, and enzyme-responsive biodegradable polymer systems have demonstrated selective drug release in preclinical tumour models with selectivity indices that look promising on paper. [57][58] The translational hurdles are compounded relative to conventional systems. The trigger signal has to be strong enough in the target tissue to produce meaningful release, absent or weak enough in normal tissues to prevent premature release, and the responsive chemical moiety has to survive manufacturing and administration conditions without partial activation. [59] No stimuli-responsive biodegradable polymer nanocarrier has cleared regulatory review, so there is no precedent package for sponsors to draw on. The full

characterisation burden, including quantitative evidence of trigger selectivity in physiologically relevant models, falls on the first programmes to try.

8.9.3 Organ-on-Chip and Microphysiological Systems

Tumour-on-chip systems consisting of human endothelial cells, tumour spheroids and physiologically representative flow conditions have generated nanoparticle deposition profiles more representative of human tumour vascular biology than subcutaneous xenograft models. The Food & Drug Administration's Centre for Drug Evaluation and Evidence points to an interest in microphysiological systems on this as regulatory-grade preclinical modalities, and the 2022 FDA Modernization Act 2.0 asks in support of alternatives to animal testing. These platforms are not ready to replace animal studies. Used as a component of a tiered preclinical strategy alongside better rodent models, they could substantially improve the predictive value of the evidence package submitted at IND.

8.9.4 PBPK Modelling

Physiologically based pharmacokinetic models incorporating MPS uptake rates, endothelial transcytosis parameters, and protein corona kinetics have reached a level of development where FDA and EMA are beginning to accept them for dose selection guidance in Phase I trials. [63] The FDA's 2022 draft guidance on PBPK analysis acknowledges nanoparticle applications. The practical limitation is limited validation data whereby most published bio distribution data sets are situated around one rodent test system, a relatively narrow particle size range, and only a small set of surface chemistries. A PBPK model fitted on that data may not transfer well to a novel formulation, and the resulting uncertainty can feed into and influence dosing recommendations in ways that are not always explicitly revealed.

8.9.5 ICH Harmonisation

The ICH Multidisciplinary Expert Working Group on Nanomaterials (4), which was established in 2021, is developing quality guidelines for application across FDA EMA PMDA, NMPA and CDSCO. [62] The work programme covers nanoparticle-specific characterisation

requirements, comparability protocols for scale-up, and reference standards for sizing methods. Progress is slow, because harmonisation across regulatory systems with different legal frameworks and institutional cultures always is. But the trajectory is correct. Sponsors planning global development programmes should track ICH MNW outputs closely, because early alignment with emerging harmonised standards will reduce the duplication of effort that currently makes multi-jurisdictional submissions so expensive.

8.10. Conclusion

The chemistry of biodegradable polymer nanocarriers is not the problem. PLGA degrades cleanly, chitosan is mucoadhesive, PCL provides long-acting release, and a generation of polymer chemists has built a broad toolkit of architectures and surface modifications on top of these foundations. The approved products, Lupron Depot, Risperdal Consta, Ozurdex, Abraxane, Bydureon, demonstrate that clinical translation is possible. What they also demonstrate, by being the exceptions rather than the rule, is that the path from promising laboratory formulation to approved product is substantially harder than the preclinical literature implies.

Three things need to change. The toxicological evaluation toolkit needs to catch up with the biology. ISO 10993 biocompatibility standards were written for macroscale implants; applying them to nanoparticle systems answers some questions and misses others, including the protein corona, CARPA risk in patients with anti-PEG antibodies, and long-term organ accumulation in patient populations with compromised MPS function. These are not academic concerns; they are the safety questions that will determine whether a clinical programme survives its IND review.

Preclinical model selection needs to improve. Subcutaneous xenograft EPR data does not predict clinical EPR-dependent drug accumulation in human tumours. BIND-014 did not fail because the researchers were careless. It failed because the model was wrong, and the field continued to use it anyway. Organ-on-chip platforms, syngeneic and orthotopic models, and humanized mouse systems are going in the right direction. Still, they must be validated with clinical outcome data before they can replace the xenograft as the main preclinical platform.

The pace of regulatory harmonisation needs to be increased. The FDA, EMA, and CDSCO have the same scientific goals but differ so much that their specific characterisation requirements, combination product classification logic, and accelerated pathway criteria impose actual costs on sponsors who are globally developing products. The ICH MNW work programme is the right mechanism for addressing this. Its progress should be faster, and industry should engage more actively with its consultation processes rather than waiting for final guidance to appear.

The last thing worth saying is about what kind of investment the field needs to make. There has been no shortage of polymer chemistry innovation. This shortfall essentially lies in the infrastructure that helps the delivery of innovations to patients. For instance, manufacturing science, standardization of analytical methods, inter-laboratory reference materials, and regulatory science are instrumental in converting academic breakthroughs into submissions that review divisions can assess with high confidence. Such investments are far from being the ones that attract a lot of attention. They simply do not yield the type of academic papers that are celebrated in academic circles and help build a career. But without them, the distance between what the field can invent and what patients can access will not close.

References

[1] Danhier et al. PLGA-based nanoparticles. J Control Release. 2012 https://doi.org/10.1016/j.jconrel.2012.01.043

[2] Ulery et al. Biomedical applications of biodegradable polymers. J Polym Sci B. 2011 https://doi.org/10.1002/polb.22259

[3] Ventola CL. Progress in nanomedicine. P T. 2017 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720487/

[4] Duncan & Gaspar. Nanomedicine(s) under the microscope. Mol Pharm. 2011 https://doi.org/10.1021/mp200394t

[5] Bobo et al. Nanoparticle-based medicines. Pharm Res. 2016 https://doi.org/10.1007/s11095-016-1958-5

[6] Khalid & El-Sawy. Polymeric nanoparticles. Int J Pharm. 2017 https://doi.org/10.1016/j.ijpharm.2017.06.052

[7] Soppimath et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001 https://doi.org/10.1016/S0168-3659(00)00339-4

[8] Kumari et al. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010 https://doi.org/10.1016/j.colsurfb.2009.09.001

[9] Tian et al. Biodegradable synthetic polymers. Prog Polym Sci. 2012 https://doi.org/10.1016/j.progpolymsci.2011.06.004

[10] Makadia & Siegel. PLGA as biodegradable controlled drug delivery carrier. Polymers. 2011 https://doi.org/10.3390/polym3031377

[11] Fu et al. Acidic environment within degrading PLGA microspheres. Pharm Res. 2000 https://doi.org/10.1023/A:1007582911958

[12] Kamaly et al. Degradable controlled-release polymers. Chem Rev. 2016 https://doi.org/10.1021/acs.chemrev.5b00346

[13] Fredenberg et al. Mechanisms of drug release in PLGA-based systems. Int J Pharm. 2011 https://doi.org/10.1016/j.ijpharm.2011.05.049

[14] Shi et al. Cancer nanomedicine. Nat Rev Cancer. 2017 https://doi.org/10.1038/nrc.2016.108

[15] Nichols & Bae. EPR: evidence and fallacy. J Control Release. 2014 https://doi.org/10.1016/j.jconrel.2014.03.057

[16] Bertrand et al. Cancer nanotechnology: passive and active targeting. Adv Drug Deliv Rev. 2014 https://doi.org/10.1016/j.addr.2013.11.009

[17] Peer et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007 https://doi.org/10.1038/nnano.2007.387

[18] Yin et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014 https://doi.org/10.1038/nrg3763

[19] Aggarwal et al. Nanoparticle interaction with plasma proteins. Adv Drug Deliv Rev. 2009 https://doi.org/10.1016/j.addr.2009.03.009

[20] Schwendeman et al. Injectable controlled release depots for large molecules. J Control Release. 2014 https://doi.org/10.1016/j.jconrel.2014.05.057

[21] Hameed et al. Chitosan nanoparticles in mucosal drug delivery. Pharmaceutics. 2022 https://doi.org/10.3390/pharmaceutics14051050

[22] Langer & Vacanti. Tissue engineering. Science. 1993 https://doi.org/10.1126/science.8493529

[23] FDA. Regulatory considerations for combination products. 2019 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-products-combination-products

[24] Lu et al. In vitro degradation of porous poly(l-lactic acid) foams. Biomaterials. 2000 https://doi.org/10.1016/S0142-9612(00)00048-6

[25] Woodruff & Hutmacher. The return of polycaprolactone. Prog Polym Sci. 2010 https://doi.org/10.1016/j.progpolymsci.2010.04.002

[26] Kroll et al. Current in vitro methods in nanoparticle risk assessment. Eur J Pharm Biopharm. 2009 https://doi.org/10.1016/j.ejpb.2008.08.009

[27] Szebeni et al. Roadmap for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018 https://doi.org/10.1038/s41565-018-0273-1

[28] Ju et al. Anti-PEG antibodies boosted by SARS-CoV-2 LNP mRNA vaccine. ACS Nano. 2022 https://doi.org/10.1021/acsnano.2c04615

[29] Nel et al. Toxic potential of materials at the nanolevel. Science. 2006 https://doi.org/10.1126/science.1114397

[30] Gustafson et al. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015 https://doi.org/10.1016/j.nantod.2015.06.006

[31] Tinkle et al. Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci. 2014 https://doi.org/10.1111/nyas.12403

[32] Monopoli et al. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012 https://doi.org/10.1038/nnano.2012.207

[33] FDA. Considering whether an FDA-regulated product involves nanotechnology. 2014 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considering-whether-fda-regulated-product-involves-application-nanotechnology

[34] European Commission. Borderline guidance: cosmetics vs. medical device regulation. 2021 https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en

[35] FDA. Nanotechnology regulatory science research plan 2017–2020 https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-regulatory-science-research-plan

[36] ICH M3(R2). Nonclinical safety studies for human clinical trials. 2009 https://www.ich.org/page/multidisciplinary-guidelines

[37] EMA. Reflection paper on intravenous liposomal products. 2013 https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator_en.pdf

[38] EMA. Guideline on pharmaceutical development of medicines for paediatric use. 2013 https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf

[39] CDSCO. Draft guidance on nanomedicine drug products containing nanomaterials. 2019 https://cdsco.gov.in/opencms/opencms/en/Guidance-Documents/

[40] WHO. Expert Committee on Specifications for Pharmaceutical Preparations: 54th report. 2020 https://www.who.int/publications/i/item/9789240008786

[41] Peltonen & Hirvonen. Physicochemical characterization of nano- and microparticles. Curr Pharm Des. 2010 https://doi.org/10.2174/138161210793563460

[42] Yu et al. Understanding pharmaceutical quality by design. AAPS J. 2014 https://doi.org/10.1208/s12248-014-9598-3

[43] Fernandez-Carballido et al. PLGA/PEG polymeric matrix and gamma-irradiation effects. Int J Pharm. 2006 https://doi.org/10.1016/j.ijpharm.2006.01.027

[44] Rao & Geckeler. Polymer nanoparticles: preparation techniques. Prog Polym Sci. 2011 https://doi.org/10.1016/j.progpolymsci.2011.01.001

[45] Fonte et al. Effect of cryoprotectants on insulin-loaded PLGA nanoparticles. Biomatter. 2012 https://doi.org/10.4161/biom.23246

[46] Faria et al. Minimum information reporting in bio-nano experimental literature. Nat Nanotechnol. 2018 https://doi.org/10.1038/s41565-018-0246-4

[47] Wacker M. Nanocarriers for intravenous injection — the long hard road to the market. Int J Pharm. 2013 https://doi.org/10.1016/j.ijpharm.2013.08.079

[48] EU MDR 2017/745. Regulation on medical devices. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745

[49] Mura et al. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013 https://doi.org/10.1038/nmat3776

[50] Okumu et al. Sustained delivery of human growth hormone — SABER system. Biomaterials. 2002 https://doi.org/10.1016/S0142-9612(02)00176-1

[51] Haller et al. Dexamethasone intravitreal implant (Ozurdex) RCT. Ophthalmology. 2010 https://doi.org/10.1016/j.ophtha.2010.03.032

[52] Gradishar et al. Phase III trial of Abraxane vs. Cremophor paclitaxel. J Clin Oncol. 2005 https://doi.org/10.1200/JCO.2005.04.937

[53] Hrkach et al. PSMA-targeted docetaxel nanoparticle (BIND-014). Sci Transl Med. 2012 https://doi.org/10.1126/scitranslmed.3003651

[54] Munoz et al. Intratumoral immunotherapy delivery and tumour microenvironment. J ImmunoTher Cancer. 2021 https://doi.org/10.1136/jitc-2020-001800

[55] Ghaffari et al. Machine learning and nanoparticle formulation. Drug Discov Today. 2022

https://doi.org/10.1016/j.drudis.2021.09.004

[56] FDA. AI and machine learning in software as a medical device. 2021 https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device

[57] Karimi et al. Smart micro/nanoparticles in stimulus-responsive drug delivery. Chem Soc Rev. 2016 https://doi.org/10.1039/C5CS00798D

[58] Fleige et al. Stimuli-responsive polymeric nanocarriers. Adv Drug Deliv Rev. 2012 https://doi.org/10.1016/j.addr.2012.01.020

[59] Cabral et al. Block copolymer micelles in nanomedicine. Chem Rev. 2018 https://doi.org/10.1021/acs.chemrev.8b00199

[60] Zhu et al. Sustainable polymers from renewable resources. Nature. 2016 https://doi.org/10.1038/nature21001

[61] ICH Q3C(R8). Guideline for residual solvents. 2021 https://www.ich.org/page/quality-guidelines

[62] ICH MNW Expert Working Group on Nanomaterials: concept paper. 2021 https://www.ich.org/page/multidisciplinary-guidelines

[63] Glassman & Muzykantov. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J Pharmacol Exp Ther. 2019 https://doi.org/10.1124/jpet.119.257113